Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

New Nonhormonal Treatments for Hot Flashes in Patients with Cancer

New Nonhormonal Treatments for Hot Flashes in Patients with Cancer

Three out of four women diagnosed with cancer before menopause experience hot flashes that can last for 7-10 years. However, the current standard treatments for hot flashes may not be suitable for all women experiencing these symptoms, also called vasomotor symptoms, particularly patients with cancer.

For hot flashes in most women younger than 60 within the first 10 years of menopause, hormone replacement therapy remains the most effective treatment option, with benefits outweighing risks. However, hormone-sensitive breast cancer makes hormone replacement therapy unsuitable; it is therefore important not to forget women who need other options.

Contraindications to hormone replacement therapy (conditions in which it should not be used) include a history of breast cancer, coronary heart disease, active liver disease, unexplained vaginal bleeding, high-risk endometrial (uterine) cancer, transient ischemic attack, and a previous venous thromboembolic event or stroke.

For vasomotor symptoms, “Fortunately, there are things in development” is a response prompted by the wide range of potential treatments currently not approved by the FDA (US Food and Drug Administration) but undergoing clinical trials.

A New Agent for Treating Hot Flashes: Oxybutynin

One of these is an antimuscarinic and anticholinergic agent currently used to treat overactive bladder and excessive sweating: oxybutynin.

In a 2016 study, 73% of women taking an escalating dose of 15 mg of oxybutynin once daily rated their symptoms as “much better,” compared with 26% in the placebo group. Women reported less frequent and less severe hot flashes and better sleep.

Subsequent studies found a 60% reduction in hot flash frequency when women took 2.5 mg of oxybutin twice daily and a 77% reduction when they took 5 mg twice daily, compared with 27% in the placebo group. Dry mouth was the only side effect reported more frequently with oxybutynin, but there was no significant difference between the treatment and placebo groups.

However, oxybutynin may have some potential long-term cognitive effects. Some studies have shown an increased risk of dementia associated with higher cumulative use of oxybutynin and anticholinergics in general.

Oxybutin is effective for menopausal symptoms, but there are some concerns about long-term use. It is probably not harmful when used briefly in women with significant and troublesome hot flashes who cannot or do not wish to use hormone therapy, and most women can tolerate the side effects. Because the drug is already primarily used to treat bladder problems, women with bladder problems would be particularly ideal candidates.

Another Treatment Agent: Estetrol (Estelle)

A new estrogen called Estetrol (E4), a naturally occurring estrogen produced by the fetal liver that crosses the placenta and has selective effects in tissues, is also being tested for menopausal symptoms. It has a long half-life of 28-32 hours, and its potential mechanism may give it a different safety profile from Estradiol (E2). It may have a lower risk of drug-drug interactions; less breast stimulation, pain or carcinogenic effect; less effect on triglycerides and a neutral effect on coagulation markers.

Although Estetrol recently received approval as an oral contraceptive under the name Estelle, it is also being investigated as a postmenopausal regimen. Preliminary findings show a 44% reduction in vasomotor symptom severity at the apparent minimum effective dose of 15 mg, compared with 30% in the placebo group. The safety profile showed no endometrial hyperplasia (thickening of the uterine lining) or unexpected side effects. In those taking 15 mg of estetrol, mean endometrial thickness increased from 2 to 6 mm but returned to baseline after progestin treatment. The 15 mg dose also increased bone turnover markers and HDL (good cholesterol) and improved glucose tolerance. However, it had no effect on coagulation parameters or triglycerides.

A New Group of Potential Agents: Kisspeptin, Neurokinin B and Dynorphin (KNDy)

Another group of potential agents being studied for hot flashes is NK3 antagonists, which aim to build on recent findings that Kisspeptin, Neurokinin B and Dynorphin (KNDy) neurons may play an important role in the etiology of vasomotor symptoms. Development of one agent, MLE 4901, was halted despite a 45% reduction in hot flashes because 3 of 28 women developed transiently elevated liver function tests at about four to six times the upper limit of normal.

The other two, fezolinetant and NT-814, are in phase 2 trials and have shown significant symptom reductions compared with placebo. In the phase 2a study, gastrointestinal effects were the most frequently reported side effects, but no participants stopped the drug because of them, and no liver test elevations occurred. In the larger phase 2b study, the most commonly reported treatment-emergent side effects were nausea, diarrhea, fatigue, urinary tract infection, sinusitis, upper respiratory tract infection, headache and cough. Five women stopped the drug because of elevated liver enzymes.

Overall, NK3 inhibitors appear generally well tolerated. There seems to be mild transaminase elevation, but it is not yet known whether this is an effect of the drug class as a whole. Follicle-stimulating hormone does not increase significantly; this matters because high FSH is associated with poor bone health, and estradiol does not increase appreciably, which is clinically important for women at high risk of breast cancer.

NK3 inhibitors would be an ideal alternative to hormone therapy for those who cannot or prefer not to use a hormonal option. However, doctors may need good education to guard against widespread discontinuation of hormone replacement therapy, particularly in women with early menopause.

Safety of New Treatments for Breast Cancer Survivors

One may wonder whether any of these new treatments have been tested in women with breast cancer and whether anything is known about taking oxybutynin at the same time as letrozole.

We know that most women with chronic illnesses have not been included in these new trials. Clinical trials appear to exclude breast cancer survivors and people taking aromatase inhibitors. Also, because clinical trials of NK3 or KNDy neuron-modulating drugs have excluded patients with cancer, these data are unlikely to be available in the very near future.

However, Lisa Larkin, a doctor who has survived breast cancer and takes tamoxifen herself, said she felt “entirely comfortable” prescribing oxybutynin to breast cancer survivors. “You can start really low, and the dry mouth really improves over time.” Larkin added that patients need to be told it takes 2 weeks to see whether it works and that side effects will eventually resolve. “It becomes very tolerable, so I encourage all of you to consider this another great option.”

Sources

New Nonhormonal Hot Flash Treatments on the Way - Medscape - Oct 06, 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Nonhormonal Treatments for Hot Flashes in Patients with Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy